Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction Results of the New York heart failure registry by Klapholz, Marc et al.
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OBJECTIVES We conducted a prospective multicenter registry in a large metropolitan area to define the
clinical characteristics, hospital course, treatment, and factors precipitating decompensation
in patients hospitalized for heart failure with a normal ejection fraction (HFNEF).
BACKGROUND The clinical profile of patients hospitalized for HFNEF has been characterized by retrospective
analyses of hospital records and state data banks, with few prospective single-center studies.
METHODS Patients hospitalized for heart failure (HF) at 24 medical centers in the New York
metropolitan area and found to have a left ventricular (LV) ejection fraction of 50% within
seven days of admission were included in this registry. Patient demographics, signs and
symptoms of HF, coexisting and exacerbating cardiovascular and medical conditions,
treatment, laboratory tests, procedures, and hospital outcomes data were collected. Analysis
by gender and race was prespecified.
RESULTS Of 619 patients, 73% were women, who were on average four years older than men (72.8 14.1
years vs. 68.6 13.8 years, p 0.001). Black non-Hispanic patients comprised 30% of the study
population. They were eight years younger than other patients (66.0  14.2 years vs. 74  13.5
years p 0.001). Co-morbid conditions and their prevalence were: hypertension, 78%; increased
LV mass, 82%; diabetes, 46%; and obesity, 46%. Before clinical decompensation that precipitated
hospitalization, 86% of patients had chronic symptoms compatible with New York Heart
Association functional classes II to IV. Factors precipitating clinical decompensation were
identified in 53% of patients. In-hospital mortality was 4.2%.
CONCLUSIONS Patients hospitalized for HFNEF are most often chronically incapacitated elderly women
with a history of hypertension and increased LV mass. Reasons for clinical decompensation
are identified in only one-half of patients. (J Am Coll Cardiol 2004;43:1432–8) © 2004 by
the American College of Cardiology Foundatione
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Tn increasing number of patients hospitalized for heart
ailure (HF) are found to have a normal left ventricular (LV)
jection fraction (EF) (1–5). The cause of HF in these
atients is thought to be related to LV diastolic dysfunction.
he clinical profile of these patients has been characterized
y retrospective analyses of hospital records and state data
anks (6–10). Few single-center studies have prospectively
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esearch Institutes, Watertown, Massachusetts; §New York Hospital, Queens, New
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inai Medical Center, New York, New York; ††Winthrop Hospital, Mineola, New
ork; ‡‡Lincoln Hospital, Bronx, New York; §§Valley Hospital, Ridgewood, New
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††Albert Einstein College of Medicine, Bronx, New York. Educational grants from
erck and GlaxoSmith-Kline pharmaceuticals supported the development of the
nternet applications and statistical analyses.
Manuscript received May 27, 2003; revised manuscript received November 8, 2003,accepted November 17, 2003.valuated patients hospitalized for heart failure with normal
jection fraction (HFNEF) (11). Therapeutic guidelines are
vailable for the treatment of patients with low-EF HF, but
o evidence-based guidelines have been developed for the
anagement of patients with HFNEF (12). Knowledge of
urrent therapeutic trends in patients with HFNEF would
e useful in assessing the feasibility of randomized placebo-
ontrolled trials aimed at assessing pharmacologic interven-
ions for these patients.
Accordingly, the New York Heart Failure Consortium
ompleted a prospective multicenter registry to characterize
he clinical profile, hospital course, and treatment of pa-
ients hospitalized for congestive HF and found to have a
ormal LVEF.
ETHODS
he New York Heart Failure consortium is composed of 24
cademic and community medical centers (Appendix). Sev-
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April 21, 2004:1432–8 Hospitalization for Normal EF Heart Failurenteen centers actively enrolled patients. The demographics
f the 7 centers that did not contribute to the registry were
imilar to those of the 17 centers that participated. Enroll-
ent began January 1, 1999, and ended June 30, 2001.
tudy population. Patients hospitalized with a primary
iagnosis of HF and found to have a normal LVEF (50%)
ithin seven days of admission were eligible. Both clinical
nd radiographic evidence were required to establish the
iagnosis of HF. Clinical evidence included pulmonary rales
nd peripheral edema. Radiographic evidence of pulmonary
ongestion was documented at each institution by an at-
ending radiologist before patient enrollment. Patients hos-
italized primarily for acute myocardial infarction or acute
oronary syndrome or with a secondary diagnosis of HF
ere excluded from the registry. However, we retained
hose patients in whom an acute coronary syndrome was not
linically recognized upon presentation but diagnosed sub-
equently on the basis of positive cardiac enzymes or new
lectrocardiographic changes. Patients satisfying eligibility
riteria were consecutively enrolled at each medical center.
ata logs within each institution and across all institutions
ere repeatedly screened to ensure that patients were
ntered into the database only once. Institutional review
oard approval was obtained at all sites.
egistry design and data collection. The registry database
onsisted of 153 variables that captured data on demograph-
cs, signs and symptoms of HF, presence of coexisting
ardiovascular and medical conditions, medications at pre-
entation and at discharge, laboratory tests, procedures, and
ospital course. Clinical history and duration of conditions,
uch as hypertension and diabetes, were based on patient
nd physician reporting and review of the medical record.
atients were characterized as having coronary artery disease
f they had a history of chronic angina, a stress test positive
or ischemia, a prior myocardial infarction, coronary steno-
es 50% by cardiac catheterization, or prior coronary
ngioplasty or coronary bypass surgery. Cardiovascular or
edical conditions that could precipitate hospitalization
ere prospectively defined. These included: severe hyper-
ension upon presentation (systolic blood pressure [BP]
200 mm Hg); severe valvular disease (regurgitation 3
r stenosis 1.0 cm2); uncontrolled supraventricular ar-
hythmia (atrial fibrillation, atrial flutter, or other supraven-
ricular tachycardia of 1 week duration or associated with
heart rate 130 beats/min); acute coronary syndrome
Abbreviations and Acronyms
B-NH  black non-Hispanic
BP  blood pressure
EF  ejection fraction
GFR  glomerular filtration rate
HF  heart failure
HFNEF  heart failure with normal ejection fraction
LV  left ventricle/ventricularecondarily diagnosed by positive cardiac enzymes or new mlectrocardiographic changes; restrictive, constrictive, or
bstructive cardiomyopathies; stroke; severe chronic ob-
tructive pulmonary disease or asthma; pneumonia; sepsis;
r serum creatinine 3.0 mg/dl. Severe chronic obstructive
ulmonary disease was determined by pulmonary function
ests or by the need for systemic steroid therapy.
Data collection and management were carried out on a
ecure web-based system called the Advanced Data Entry
nd Protocol Tracking (New England Research Institutes,
atertown, Massachusetts). This system has multiple tools
o immediately assess the validity and completeness of data
eing entered and to provide real-time feedback to individ-
al sites on incomplete, missing, or incorrect data.
etermination of LVEF. The LVEF was obtained by
wo-dimensional echocardiography or gated radionuclide
entriculography. Only patients with a normal (50%)
VEF were eligible. Echocardiograms or nuclear scans were
nterpreted by experienced observers without knowledge of
patient’s inclusion into the registry. The EF by two-
imensional echocardiography was determined by a visual
stimate based on an assessment of LV contractile function
n multiple echocardiographic views. The accuracy and
eproducibility of visual estimates of LVEF have been
reviously established (13). The EF by gated radionuclide
entriculography was calculated from the LV time-activity
urve (14).
chocardiographic analysis. The LV internal dimensions
nd wall thicknesses were measured according to the rec-
mmendations of the American Society of Echocardiogra-
hy (15). Wall motion was assessed in the parasternal
ong- and short-axis views and apical two-, three-, and
our-chamber views. Presence and severity of mitral and
ortic regurgitation were assessed with color Doppler im-
ging and image-guided pulsed Doppler studies with semi-
uantitative grading (16). Aortic valve area was calculated
rom the continuity equation and mitral valve area from
ressure half-time analysis. Right ventricular systolic pres-
ure was calculated from the measurement of tricuspid
egurgitation blood flow velocity using the modified Ber-
oulli equation and an assumed right atrial pressure of 10
m Hg. Cardiac mass was calculated using the Penn
onvention (17). Mass was indexed by height2.7 (m), with
artition values of 46.7 g/m2.7 in women and 49.2 g/m2.7 in
en to define increased LV mass (18).
enal function. Glomerular filtration rate (GFR) (ml/
in) was calculated using a modified Cockgroft-Gault
ormula: GFR  (140  age/creatinine)  (calculated
eight/72)  (0.85 for female), where calculated weight
kg)  ideal weight (kg)  0.4  (actual weight  ideal
eight) and ideal weight  51.65  (1.85  [height
inches)]  60]) for men and 48.67  (1.65  [height
inches)  60]) for women (19).
ody mass index. Body mass index was calculated as
eight (kg)/height2 (m). Obesity was defined by a body
ass index 30 (20).
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Hospitalization for Normal EF Heart Failure April 21, 2004:1432–8tatistical methods. Summary statistics are presented as
ean  standard deviation for continuous data or median
nd interquartile range where indicated and percentages for
ategorical data. For comparisons by gender and race,
tudent’s t test was used to compare the distributions of
ormally distributed variables and the Wilcoxon rank sum
est was used to compare the distributions of non-normally
istributed variables determined by the examination of Q-Q
lots and the Shapiro-Wilk test for normality p value. The
isher exact test was used to compare group proportions.
ifferences between presentation and discharge medical
egimen were assessed using McNemar’s test for agreement.
he signed rank test was used to assess the difference
etween presentation and discharge systolic and diastolic
Ps. Linear regression was used to examine differences in
emodynamic and cardiac measures by race and gender
djusted for covariates that differed by race and gender. The
kewed outcome measure GFR was log-transformed before
inear regression analysis. Least-squares means are reported
o express covariate-adjusted mean values by race and
ender. Logistic regression analysis was used to examine
ifferences by race and gender in the use of medications
djusted for covariates such as blood pressure and age.
Only p values of 0.01 were considered statistically
ignificant. Analyses were conducted with the Statistical
nalysis System Version 8.1 (SAS Institute, Cary, North
arolina) and S-Plus 2000 (S-Plus, Insightful Corp., Seat-
le, Washington) software.
ESULTS
linical characteristics and co-morbid conditions. A to-
al of 619 patients (mean age 71.7  14.1 years, range 22 to
06 years) were enrolled. Four hundred forty-nine patients
72.5%) were women and 170 (27.5%) were men. Women
Table 1. Clinical Characteristics and Co-Morb
61
Age (yrs)* 7
History of hypertension
Systolic BP (mm Hg, on presentation) 15
Diastolic BP (mm Hg, on presentation) 8
Diabetes mellitus
Coronary artery disease
History of COPD or asthma
Atrial fibrillation
Atrial flutter
Supraventricular tachycardia
Hypothyroidism
Hemoglobin (mg/dl) 1
Glomerular filtration rate† (ml/min) 5
Dialysis
Body mass index (n  509) 3
Body mass index 30 (n  509)
Quantitative values are mean  SD. *Age was the only statis
To avoid type 1 error only p values0.01 are significant (see M
for glomerular filtration rate calculation; p value adjusted for
BP  blood pressure; COPD  chronic obstructive pulmere on average four years older than men: 72.8  14.1 wears versus 68.6  13.8 years (p  0.001). Before hospi-
alization, 75% of patients had chronic symptoms compat-
ble with New York Heart Association functional class II or
II, 14% of patients had chronic symptoms compatible with
unctional class I, and 11% had chronic symptoms with
unctional class IV.
The LVEF was measured by echocardiography in 96% of
atients and by nuclear imaging in 4% of patients. Mea-
urement of LVEF was obtained within three days of
dmission in 83% of patients and within seven days in all
atients. Women and men had identical mean LVEF: 59.9
7.2% and 59.7  7.4%, respectively.
Patients had multiple co-morbid conditions (Table 1).
ypertension was the most common with a mean duration
f 14 years (median 10.5 years; interquartile range 7 to 20
ears). The BP upon presentation and prevalence of hyper-
ension were similar in women and men. The second most
ommon co-morbid conditions were diabetes and obesity,
ith a similar prevalence in the total population (46%) and
etween women and men. Eighty-eight percent of diabetics
ere treated with oral hypoglycemic agents and/or insulin
nd 10% were treated with diet alone. Their mean hemo-
lobin A1C was 8.2 2.4%. Forty-three percent of patients
ad coronary artery disease. Atrial fibrillation was present in
early one-quarter of patients.
wo-dimensional echocardiographic Doppler findings.
chocardiographic and Doppler parameters are summarized in
able 2. Chamber dimensions were normal in women and
en. Eighty-three percent of women and 81% of men had
ncreased LV mass with a similar median LV mass index: 66.9
ersus 65.7 g/m2.7 (p 0.92). Moderate pulmonary hyperten-
ion, as evidenced by a mean right ventricular systolic BP of 47
17 mm Hg, was observed in 272 patients whose clinical
haracteristics, including the presence of pulmonary disease,
onditions
al
0%)
Women
449 (72.5%)
Men
170 (27.5%)
14.1 72.8  14.1 68.6  13.8
% 78.8% 76.3%
35.5 158.8  34.3 162.2  38.5
20.4 82.9  19.7 86.3  22.1
% 44.9% 48.5%
% 42.3% 45.1%
% 25.1% 22.9%
% 22.7% 25.3%
% 1.3% 4.1%
% 0.5% 1.8%
% 11.3% 5.1%
2.2 11.7  2.0 12.2  2.4
28.5 50.1  22.7‡ 52.7  22.8‡
% 3.6% 7.1%
8.8 30.8  8.9 30.2  8.3
% 46.9% 44.4%
significant difference between women and men (p  0.001).
ds). †Excluding patients on dialysis, n 483. ‡See Methods
disease.id C
Tot
9 (10
1.7 
78.2
9.7 
3.9 
45.9
43.1
24.5
23.4
2.1
0.8
9.7
1.8 
0.8 
4.5
0.6 
46.2
tically
etho
age.ere similar to those of the entire cohort.
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April 21, 2004:1432–8 Hospitalization for Normal EF Heart Failureactors precipitating hospitalization. Symptomatic de-
erioration precipitating hospitalization was related to
xacerbation or poor control of coexisting conditions in
1% of patients and to new events in 2%. Except for
evere valvular heart disease (combined prevalence of
evere regurgitation and stenosis, 13.9%), severe hyper-
ension (prevalence 13%), and acknowledged non-
ompliance to medication (prevalence 12.8%), the prev-
lence of all other precipitating factors was below 10%
Fig. 1). Two or more precipitating factors were present
n 19.3% of patients.
iagnostic procedures and hospital course. Sixty-three
atients (10%) underwent cardiac stress testing, which was
able 2. Two-Dimensional and Doppler Echocardiographic Para
Total
(n  619)
V systolic diameter (cm) 3.21  0.73 3
V diastolic diameter (cm) 4.70  0.76 4
VSP (mm Hg) (n  272) 46.5  17.1 4
edian LVMI (g/m2.7) (Q1,Q3) (n  360) 66.5 (53.4, 84.8) 66
itral regurgitation 1§ 62.9%
itral regurgitation 3§ 9.9%
ortic regurgitation 1§ 27.8%
ortic regurgitation 3§ 2.3%
itral stenosis 3.6%
itral stenosis with MVA  1.0 cm2 0.8%
ortic stenosis 8.4%
ortic stenosis with AVA  1.0 cm2 2.8%
uantitative values are mean  SD. *The only statistically significant difference betw
values 0.01 are significant (see Methods). †There were no significant differences
see Methods). ‡p Values adjusted for body surface area. §Semiquantitative scale 1
AVA  aortic valve area; LV  left ventricle; LVMI  left ventricular mass index
25th percentile); Q3  third quartile (75th percentile).
igure 1. Cardiovascular or medical conditions and new events precipitat
pon presentation (emergency department); †non-compliance  non-com
severity scale from 1 to 4); §ACS  acute coronary syndrome; baseline
utter/supraventricular tachycardia—1 week duration or heart rate 1
efined by pulmonary function tests or by the need for systemic steroid therapyositive for ischemia in 28 patients. Fifty-six patients (9%)
nderwent coronary angiography that revealed one or more
tenoses 70% in 34 patients. Thirty-one patients (5%)
nderwent right heart catheterization.
Mean BPs at discharge were within normal values for
oth women and men: 131/71 and 134/73 mm Hg, respec-
ively. Mean and median lengths of stay were 8.8 and 6.0
ays, respectively. In-hospital mortality was 4.2%. Patients
ho died were significantly older than patients who sur-
ived: 78.9  14.3 years versus 71.3  14.1 years (p 
.01). Gender, the presence of co-morbid conditions, or
recipitating factors for hospitalization did not affect length
f stay or mortality.
rs
en*
449)
Men*
(n  170)
Black-NH†
(n  184)
Other Race†
(n  430)
0.72‡ 3.34  0.74‡ 3.22  0.72‡ 3.24  0.72‡
0.70‡ 4.90  0.72‡ 4.67  0.71‡ 4.75  0.70‡
17.2 47.7  16.9 47.3  16.9 46.0  17.2
.4, 84.7) 65.7 (52.5, 85.4) 68.5 (53.3, 89.2) 66.0 (53.4, 84.5)
3% 59.2% 66.7% 61.3%
6% 5.4% 11.7% 9.3%
4% 26.0% 25.7% 28.5%
5% 1.8% 3.9% 1.6%
2% 1.8% 2.2% 4.2%
9% 0.6% 0.0% 1.2%
0% 9.5% 4.9% 10.0%
2% 1.8% 1.1% 3.5%
omen and men was LV diastolic diameter (p  0.005). To avoid type 1 error, only
after adjustment for age. To avoid type 1, error only p values 0.01 are significant
.
 mitral valve area; RVSP  right ventricular systolic pressure; Q1  first quartile
spitalization. Ranked by prevalence. *Syst. BP  systolic blood pressure
ce with medication; ‡MR/AR  mitral regurgitation/aortic regurgitation
sis or creatinine 3 mg/dl; ¶Afib/Flutter/SVT atrial fibrillation or atrial
ats/min; #COPD  chronic obstructive pulmonary disease—severe wasmete
Wom
(n 
.18 
.67 
6.1 
.9 (53
64.
11.
28.
2.
4.
0.
8.
3.
een w
by race
to 4
; MVAing ho
plian
dialy
30 be
; **AS/MS  aortic stenosis/mitral stenosis.
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Hospitalization for Normal EF Heart Failure April 21, 2004:1432–8edications. Medications at presentation and at discharge
re shown in Figure 2. Therapeutic adjustments during
ospitalization included an absolute increase in the percent-
ge of patients receiving diuretics by 12.8% (p  0.001),
ngiotensin-converting enzyme inhibitors by 12.6% (p 
.001), aldactone by 3.5% (p  0.001), and beta-adrenergic
lockers by 6.1% (p  0.002). The percentage of patients
eceiving digoxin, calcium channel blockers, and angioten-
in receptor blockers remained unchanged.
atient profile by race. One hundred eighty-four patients
30%) were black non-Hispanic (B-NH). As observed in
he entire cohort, 72% of the B-NH patients were women.
he B-NH patients were on average eight years younger
han patients of other racial background: 67.1 14.3 versus
ears 75.1  13.4 years for women (p  0.001), and 62.9 
3.5 years versus 71.1  13.3 years for men (p  0.001).
oth LVEF and the percentage of patients with New York
eart Association functional class II to IV were similar in
-NH patients and in others: 59.0  7.7% versus 60.3 
.0% (p  0.04) and 80% versus 88% (p  0.03), respec-
ively. A greater percentage of B-NH patients had a history
f hypertension: 86% versus 74% (p 0.001). Mean systolic
nd diastolic BPs upon presentation and at discharge were
ignificantly greater in B-NH patients than in others (Fig.
). However, the percentage of patients with increased LV
ass was comparable: 84% versus 82% (p  0.65). Obesity
body mass index 30) was more prevalent in B-NH
omen than in other women: 59% versus 41% (p  0.002).
Age-corrected GFR, after excluding patients on dialysis,
as significantly lower in B-NH patients than in others:
7.7  23.3 ml/min versus 52.3  22.9 ml/min (p 
.008). The use of long-term hemodialysis was 7.1% in
-NH patients and 3.3% in others (p  0.05). After
djusting for higher BPs in B-NH patients, the use of
ngiotensin-converting enzyme inhibitors did not differ
ignificantly in B-NH patients compared with others: 48%
ersus 35.8% upon presentation (unadjusted p  0.006, BP
djusted p  0.045) and 61.2% versus 48.7% at discharge
unadjusted p  0.005, BP adjusted p  0.110). Racial
ackground did not affect in-hospital mortality or length of
igure 2. Percentage of patients at presentation (open bars), and at
ischarge (solid bars) receiving diuretics, angiotensin-converting enzyme
nhibitors (ACEI), beta-blockers (BB), calcium channel blockers (CCB),
igoxin (DIG), angiotensin II receptor blockers (ARB), and aldactone
ALDACT).tay. hISCUSSION
ur registry provides a comprehensive description of the
linical characteristics, hospital course, and treatment of
atients hospitalized for HFNEF. It highlights the severity
f symptoms before decompensation, the high prevalence of
substantially increased LV mass, and clinical differences
ccording to racial background. Lastly, factors that precip-
tate hospitalization are identifiable in only one-half of
atients hospitalized for HFNEF.
iagnosis of diastolic HF. When LVEF is normal, HF is
ttributed to diastolic dysfunction and labeled diastolic HF.
owever, because it is difficult to noninvasively assess LV
iastolic function, the criteria required to diagnose diastolic
F remain uncertain (21–23). Vasan and Levy (24) sought
o strengthen the diagnosis of diastolic HF by requiring a
horter interval between the HF event and documentation
f a normal LVEF. Accordingly, the diagnosis of diastolic
F was probable in 84% of our patients. Previous studies
ealt with only possible diastolic HF as the interval between
resentation and measurement of LV function was either
ot recorded or could be as long as one year (6–10,25,26).
he criteria required to diagnose HF in the present registry
ere also more stringent than the criteria in prior reports
ealing with hospitalized patients, as we required both
linical and radiographic findings to document the diagnosis
f HF (6–11,25,26).
The presence of diastolic abnormalities in patients with
resumed diastolic HF has recently been questioned (27). In
articular, the contribution of arterial stiffening and renal
ysfunction, common to the elderly, is increasingly enter-
ained as a mechanism that might help precipitate HFNEF
28,29).
linical characteristics. Nearly three-quarters of patients
ospitalized for HFNEF in the New York metropolitan
rea are elderly women with increased LV mass and a
igure 3. Mean systolic (hatched bars) and diastolic (solid bars) blood
ressures upon presentation (emergency department) and at discharge in
he entire cohort of patients (Total) and according to racial background
Black non-Hispanic [B-NH] and Others). Blood pressure (mm Hg) upon
resentation: B-NH 172 of 92, Other 155 of 81, Total 160 of 84. Blood
ressure (mm Hg) on discharge: B-NH 137 of 75, Other 130 of 71, Total
32 of 72.istory of hypertension. Between the ages of 65 and 74
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April 21, 2004:1432–8 Hospitalization for Normal EF Heart Failureears, women represent 56% of the population in New York
tate (30). The modest predominance of women in the
lderly population cannot account for the high prevalence of
omen in the present registry. The mechanisms responsible
or the prevalence of HFNEF in women are unclear.
ender affects cardiac remodeling. When confronted with
ressure overload, the LV hypertrophies more and dilates
ess in women than men (31). A reduced rate of myocyte
oss in women and transcriptional regulation by estrogens of
enes implicated in cardiac hypertrophy may contribute to
ersistent gender related differences in cardiac remodeling
11,24,31–33).
The prevalence of coronary artery disease in our patients
as similar to that of previous reports (7,11,25). In contrast,
he prevalence of diabetes in our patients (46%) was greater
han the range previously reported in this patient population
23% to 33%) (8,9,11,25,34). The greater prevalence of
iabetes is concordant with the high prevalence of obesity
oted in our patients, an observation that was also made in
he Strong Heart Study (10). The association of diabetes,
ypertension, and obesity in 24% of our patients suggests
he possibility of a high prevalence of the metabolic syn-
rome in our population. (10,34–36).
hronicity of symptoms. Eighty-five percent of our pa-
ients had chronic overt symptoms of HF that antedated
heir hospitalization. Functional intolerance and moderate
ulmonary hypertension most likely result from chronic
levation of LV filling pressures (37). The marginal status of
ur patients at baseline renders the identification of precip-
tating factors for hospitalization difficult, as these factors
re likely to be modest in nature. The present experience is
imilar to that in patients with HF due to LV systolic
ysfunction, where precipitating factors are often not iden-
ified but generally thought to be related to medical and
ietary non-compliance (38).
herapy. Despite conflicting views regarding the use of
ngiotensin-converting enzyme inhibitors in patients with
iastolic HF, they were, after diuretics, the medications
ost often prescribed to our patients (8,39). Angiotensin II
eceptor blockade with losartan has been shown to substan-
ially reduce LV hypertrophy in hypertensive patients with
ncreased LV mass (40). Definite evidence supporting mod-
lation of the renin-angiotensin system in patients with HF
nd preserved systolic function (EF 40%) awaits the
esults of ongoing double-blind, randomized placebo-
ontrolled trials (41,42).
acial differences. Racial profiling in medical research
eeds to be interpreted with caution. Despite their signifi-
antly younger age, B-NH patients presented with more
evere hypertension and worse renal function than others.
ur data are consistent with the higher prevalence of end
rgan damage in B-NH hypertensive patients. Obesity was
lso particularly prevalent in B-NH women compared with
ther women. Despite their reported reduced efficacy in
frican Americans, angiotensin-converting enzyme inhibi-ors tended to be prescribed at least as often in B-NH
atients as in others (43).
tudy limitations. The present study has several limita-
ions. There was no echocardiographic core laboratory to
nsure uniform quality control of all imaging studies. To
ddress the issue of validity of echocardiographic measure-
ents, we performed a “by center analysis” of LV mass
ndex that incorporates measures of wall thickness and
hamber dimensions and is corrected for height. There were
ome differences in mean height-corrected LV mass by site
p  0.04), but when examined as a threshold measure
defined as elevated LV mass 46.7 g/m2.7 in women and
49.2 g/m2.7 in men), the prevalence of this condition was
ound to be similar among all sites (p  0.38). The
easurement of B-type natriuretic peptide was not com-
ercially available when the registry was initiated. Standard
oad-dependent echocardiographic parameters of LV dia-
tolic dysfunction were not collected and the technical
bility to collect load-independent (tissue Doppler) param-
ters was not available at all sites. Last, we did not mandate
hat all patients undergo cardiac stress testing to unmask
ccult coronary disease or require serum in all patients for
emoglobin A1C determinations; we relied on physician
linical judgment. Thus, the prevalence of coronary artery
isease or diabetes mellitus may have been underestimated.
e also recognize that when defined according to recent
uidelines, the duration and prevalence of hypertension and
iabetes in our patient population may be underestimated as
he physiologic thresholds for establishing these diagnoses
ontinue to be lowered.
In summary, patients hospitalized in the New York
etropolitan area for HFNEF are preponderantly elderly
omen with a history of hypertension and increased LV
ass. The chronic disability of these patients and the
requent inability to identify a factor precipitating hospital-
zation points to an absence of functional reserve and the
eed to develop aggressive treatment strategies.
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PPENDIX
or a list of the New York Heart Failure Consortium
edical Centers, please see the April 21, 2004, issue of
ACC at http://www.cardiosource.com/jacc.html.
